CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis.
CD147/EMMPRIN (extracellular matrix metalloproteinase inducer) plays an important role in tumor progression and a number of studies have suggested that it is an indicator of tumor prognosis. This current meta-analysis systematically reevaluated the predictive potential of CD147/EMMPRIN in various cancers. We searched PubMed and Embase databases to screen the literature. Fixed-effect and random-effect meta-analytical techniques were used to correlate CD147 expression with outcome measures. A total of 53 studies that included 68 datasets were eligible for inclusion in the final analysis. We found a significant association between CD147/EMMPRIN overexpression and adverse tumor outcomes, such as overall survival, disease-specific survival, progression-free survival, metastasis-free survival or recurrence-free survival, irrespective of the model analysis. In addition, CD147/EMMPRIN overexpression predicted a high risk for chemotherapy drugs resistance. CD147/EMMPRIN is a central player in tumor progression and predicts a poor prognosis, including in patients who have received chemo-radiotherapy. Our results provide the evidence that CD147/EMMPRIN could be a potential therapeutic target for cancers.
Department of Gynecology and Obstetrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277, Jiefang Avenue, Jiangan District, 430022 Wuhan P. R. China.
Xiaoyan
X
Xin
Department of Pathophysiology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, No. 13, Hangkong Road, Qiaokou District, 430030 Wuhan P. R. China.
Xianqin
X
Zeng
Department of General Surgery, Affiliated Hospital of Guizhou Medical College, No. 28, Guiyi Street, Yunyan District, 550000 Guiyang P. R. China.
Huajian
H
Gu
Department of Gynecology and Obstetrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277, Jiefang Avenue, Jiangan District, 430022 Wuhan P. R. China.|Department of Gynaecology, Shanghai Clinical Center of Chinese Academy of Science, Shanghai, 100864 P. R. China.
Min
M
Li
Department of Gynecology and Obstetrics, Shenzhen Tumor Hospital, No. 113, Baohe Avenue, Longgang District, 518116 Shenzhen, P. R. China.
Huaming
H
Tan
Department of Gynecology and Obstetrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277, Jiefang Avenue, Jiangan District, 430022 Wuhan P. R. China.
Zhishan
Z
Jin
Department of Gynecology and Obstetrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277, Jiefang Avenue, Jiangan District, 430022 Wuhan P. R. China.
Teng
T
Hua
Department of Gynecology and Obstetrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277, Jiefang Avenue, Jiangan District, 430022 Wuhan P. R. China.
Rui
R
Shi
Department of Gynecology and Obstetrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277, Jiefang Avenue, Jiangan District, 430022 Wuhan P. R. China.
Hongbo
H
Wang
D051926:Basigin / Q000378:metabolism*; D014408:Biomarkers, Tumor / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000378:metabolism*; D011379:Prognosis; D016019:Survival Analysis; D015854:Up-Regulation
C497886:BSG protein, human; D014408:Biomarkers, Tumor; D051926:Basigin